Absci falls after Q2 revenue misses estimates
BUZZ-Absci falls after Q2 revenue misses estimates ** Shares of drug developer Absci ABSI.O fall 1.4% to $9.3
** Co posts Q2 revenue of $318,000, sharply below analysts' estimates of $1.2 mln
** Reports increase in R&D expenses of $22.6 mln compared to $20.5 mln last year, primarily driven by advancement of ABSI's internal programs
** Brokerage TD Cowen says revenue is expected to nearly halve due to lower collaboration and milestone payments, underscoring its reliance on partner-funded revenue
** Says investors are pivoting the attention to its ABS-201 hair-loss data expected later this year- TD Cowen
** Nine of 10 brokerages rate the stock "buy" or higher and one "hold"; median PT is $14- LSEG data
** Including session's move, stock has more than doubled in value, YTD
(Reporting by Anand Gopal in Bengaluru)
Recent news on AbSci
See all newsAbsci Corp reports results for the quarter ended September 30 - Earnings Summary
Brief: Absci Corp Files For Mixed Shelf Size Not Disclosed - SEC Filing
Absci Q3 revenue misses estimates, net loss widens on R&D spends
Focus: Beyond the Scale: Men turn to cosmetic clinics to complete weight-loss transformation
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave